Membership on the Board of the Alliance for Biosecurity is open to research-based pharmaceutical and biotech companies. 

Membership fees are $2,300 per company per month and have not increased for over six years. Membership includes:

  • Twice yearly Alliance Board meetings.
  • Guest officials from ASPR, BARDA, and other government offices.
  • Continuous, evolving advocacy work.
  • Regular public relations outreach.


Associate membership is available to contract research laboratories and other entities, as approved by the Board.

To find out how to join the Alliance or to obtain additional information, please call us at (202) 457-6331, email, or reach out using the form on our ‘Contact Us’ page.

Additional Membership Benefits


messaging behind our common goals in funding and public policy.

Lower costs

for advocacy, communications, and monitoring efforts.

Engage efficiently

with policymakers as a group of companies.

Team up

with likeminded organizations.

Our Priorities

  • Advocate for funding to develop, manufacture, and procure medical countermeasures (MCMs).
  • Educate Members of Congress, other government stakeholders, and the media on pressing preparedness and response issues.
  • Influence key public policy discussions and decisions regarding critical biodefense topics.
  • Promote the shared goals of ASPR and BARDA.
  • Provide a venue for industry dialogue to share information, experiences, and best practices.
  • Develop industry consensus on priority biosecurity policies.
  • Serve as a trusted and go-to industry resource for Congress, the Administration, and press.

A Record of Accomplishments

  • Serve as a trusted industry resource for the Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA) – including by participating in a small group of industry representatives advising ASPR – while promoting collaboration by and transparency within public-private partnerships.
  • Consistently secure annual funding increases in federal appropriations legislation for key biodefense programs including BARDA, the Strategic National Stockpile (SNS), Project BioShield Special Reserve Fund (SRF), and Pandemic Influenza Preparedness.
  • 2018 PAHPA Reauthorization: Secured the transition of SNS management and oversight to ASPR; championed the inclusion of Pandemic Influenza Preparedness as a line-item in annual appropriations bills and garnered support for funding specifically focused on Emerging Infectious Diseases (EIDs); and secured an extension of the Medical Countermeasures (MCM) Priority Review Voucher (PRV) Program, which is currently being considered for an additional extension.
  • Secured Congressional support for – and continue work to include in PAHPA reauthorization – the creation of a Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Advisory Committee to facilitate increased collaboration among government and industry, enhance transparency and communication, and identify funding levels necessary for continued MCM research and development.
  • Facilitated industry participation in the whole-of-government response to the COVID-19 pandemic by advising on the creation and participating in the work of Operation Warp Speed (OWS), as well as documenting Alliance member pandemic response capabilities.
  • Led industry efforts in coordinating with Congress to establish the Congressional Biodefense Caucus as a forum to educate Members of Congress and staff on ways industry works with government to support America’s preparedness and response efforts.
  • Conducted a National Biosecurity Survey to understand the electorate’s support for America’s biodefense programs and leveraged the results to raise awareness and recruit new industry champions in Congress.